A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This study is testing a new experimental drug called STAR0602 to see if it is safe and effective for treating certain advanced solid tumors. The goal is to find a new way to help patients whose cancer has spread or cannot be removed by surgery.

You may be eligible if you have an advanced solid tumor that has not responded well to previous treatments. Researchers are specifically looking for patients whose tumors have certain genetic patterns or are linked to specific viral infections.

Participants will receive the study drug intravenously, which means it is delivered through a vein in your arm. The research team will closely monitor you throughout the study to check for side effects and see how well the drug works against your cancer.

The study is currently recruiting patients at medical centers in Loma Linda and Sacramento, California, as well as Denver, Colorado. Please contact these sites to discuss if this study is the right fit for your specific health situation.